The Melbourne TheranosticInnovation Centre (MTIC) is pleased to announce the successfulfirst-in-human administration of our 10th novel radiopharmaceutical spanningboth diagnostics and therapies.
This represents a significantstep in our mission to rigorously evaluate innovative theranostic agents undercarefully designed clinical protocols. Each first-in-human study not onlyexpands our understanding of tracer kinetics, biodistribution, safety andefficacy, but also contributes to the growing body of evidence guiding thedevelopment of new diagnostic and therapeutic paradigms in nuclear medicine.
This milestone reflects thededication of our multidisciplinary team and the collaboration of our academic,industry, and clinical partners. Above all, we acknowledge the patients whomake these studies possible and whose participation drives the advancement ofprecision medicine.
